{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:06:23Z","timestamp":1776902783129,"version":"3.51.2"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heart failure with preserved ejection fraction (HFpEF) traditionally has been characterized as a form of heart failure without therapeutic options, in particular with a lack of response to the established therapies of heart failure with reduced ejection fraction (HFrEF). However, this is no longer true. Besides physical exercise, risk factor modification, aldosterone blocking agents, and sodium-glucose cotransporter 2 inhibitors, specific therapies are emerging for specific HFpEF etiologies, such as hypertrophic cardiomyopathy or cardiac amyloidosis. This development justifies increased efforts to arrive at specific diagnoses within the umbrella of HFpEF. Cardiac imaging plays by far the largest role in this effort and is discussed in the following review.<\/jats:p>","DOI":"10.1093\/ehjci\/jead137","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T20:10:24Z","timestamp":1688415024000},"page":"1343-1351","source":"Crossref","is-referenced-by-count":7,"title":["The role of imaging in the selection of patients for HFpEF therapy"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-557X","authenticated-orcid":false,"given":"Tomasz","family":"Baron","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Clinical Physiology, Uppsala University and Uppsala University Hospital , 751 85 Uppsala , Sweden"},{"name":"Uppsala Clinical Research , 751 85 Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-1993","authenticated-orcid":false,"given":"Spyridon","family":"Gerovasileiou","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Clinical Physiology, Uppsala University and Uppsala University Hospital , 751 85 Uppsala , Sweden"},{"name":"VO Medicin, Lasarettet i Enk\u00f6ping , all 785 81 Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-278X","authenticated-orcid":false,"given":"Frank A","family":"Flachskampf","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Clinical Physiology, Uppsala University and Uppsala University Hospital , 751 85 Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2023102011135254400_jead137-B1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the ex-DHF (exercise training in diastolic heart failure) pilot study","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023102011135254400_jead137-B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2023102011135254400_jead137-B6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023102011135254400_jead137-B7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2023102011135254400_jead137-B8","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 Esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B9","first-page":"e895","article-title":"2022 Aha\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 Acc expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B11","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ccd.29863","article-title":"Coronary microcirculation assessment using functional angiography: development of a wire-free method applicable to conventional coronary angiograms","volume":"98","author":"Mejia-Renteria","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"2023102011135254400_jead137-B14","doi-asserted-by":"crossref","first-page":"1060764","DOI":"10.3389\/fcvm.2022.1060764","article-title":"Coronary microvascular dysfunction as assessed by angiography-derived index of microvascular resistance co-localizes with and may explain the presence of ischemia in stress-cardiac magnetic resonance imaging in the absence of coronary artery disease","volume":"9","author":"Milzi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023102011135254400_jead137-B15","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.jcmg.2018.08.018","article-title":"Global coronary flow reserve measured during stress cardiac magnetic resonance imaging is an independent predictor of adverse cardiovascular events","volume":"12","author":"Indorkar","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ehjcvp\/pvu020","article-title":"Pharmacotherapy for coronary microvascular dysfunction","volume":"1","author":"Ong","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023102011135254400_jead137-B17","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2023102011135254400_jead137-B18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"2023102011135254400_jead137-B20","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B21","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B22","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B24","first-page":"1","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2022","journal-title":"Amyloid"},{"key":"2023102011135254400_jead137-B25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B26","first-page":"e000029","article-title":"Asnc\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11886-022-01703-7","article-title":"Imaging-Guided treatment for cardiac amyloidosis","volume":"24","author":"Ioannou","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"2023102011135254400_jead137-B28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-Verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B29","first-page":"jead119.004","article-title":"Tracking multiorgan treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping","volume":"24","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2023102011135254400_jead137-B31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol Genet Metab"},{"key":"2023102011135254400_jead137-B33","article-title":"Effects of enzyme-replacement-therapy on cardiac-magnetic-resonance findings in Fabry disease: A systematic review and meta-analysis ERT impact on CMR parameters in Fabry disease (abstract)","volume":"24","author":"Figliozzi","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2023102011135254400_jead137-B34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and screening of patients with Fabry disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2023102011135254400_jead137-B35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy in Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1-2","key":"2023102011135254400_jead137-B37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Feldt-Rasmussen","year":"2020","journal-title":"Mol Genet Metab"},{"key":"2023102011135254400_jead137-B38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (famous)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023102011135254400_jead137-B39","first-page":"jmg-2022-108768","article-title":"Effect of migalastat on cArdiac involvement in FabRry disease: MAIORA study","author":"Camporeale","year":"2023","journal-title":"J Med Genet"},{"key":"2023102011135254400_jead137-B40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ehjci\/jeu291","article-title":"Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European association of cardiovascular imaging endorsed by the Saudi heart association","volume":"16","author":"Cardim","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B41","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/hrt.2003.031161","article-title":"Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy","volume":"91","author":"Thaman","year":"2005","journal-title":"Heart"},{"key":"2023102011135254400_jead137-B42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.euje.2004.01.001","article-title":"Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience","volume":"5","author":"Faber","year":"2004","journal-title":"Eur J Echocardiogr"},{"key":"2023102011135254400_jead137-B45","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 Esc guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B46","first-page":"e533","article-title":"2020 Aha\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: A report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2023102011135254400_jead137-B48","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B49","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B51","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.007878","article-title":"Noninvasive multimodality imaging for the diagnosis of constrictive pericarditis","volume":"11","author":"Alajaji","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.7326\/0003-4819-132-6-200003210-00004","article-title":"Calcific constrictive pericarditis: is it still with US?","volume":"132","author":"Ling","year":"2000","journal-title":"Ann Intern Med"},{"key":"2023102011135254400_jead137-B53","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/01.CIR.0000087606.18453.FD","article-title":"Constrictive pericarditis in 26 patients with histologically normal pericardial thickness","volume":"108","author":"Talreja","year":"2003","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B54","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCIMAGING.113.001613","article-title":"Echocardiographic diagnosis of constrictive pericarditis: mayo clinic criteria","volume":"7","author":"Welch","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B55","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B56","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.111.050773","article-title":"Iron overload cardiomyopathy in clinical practice","volume":"124","author":"Kremastinos","year":"2011","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/RMR.0000000000000011","article-title":"T2* imaging of the heart: methods, applications, and outcomes","volume":"23","author":"Baksi","year":"2014","journal-title":"Top Magn Reson Imaging"},{"key":"2023102011135254400_jead137-B58","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"2023102011135254400_jead137-B59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12968-015-0207-0","article-title":"T1 at 1.5 T and 3 T compared with conventional T2* at 1.5 T for cardiac siderosis","volume":"17","author":"Alam","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023102011135254400_jead137-B60","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00277-020-04117-z","article-title":"Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up","volume":"99","author":"Daar","year":"2020","journal-title":"Ann Hematol"},{"key":"2023102011135254400_jead137-B61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 Esc\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B62","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcmg.2022.08.016","article-title":"Atrial functional mitral regurgitation: A JACC: cardiovascular imaging expert panel viewpoint","volume":"15","author":"Zoghbi","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B63","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/ehf2.13896","article-title":"Influence of catheter ablation for atrial fibrillation on atrial and ventricular functional mitral regurgitation","volume":"9","author":"Masuda","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2023102011135254400_jead137-B64","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023102011135254400_jead137-B65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2967\/jnumed.111.090662","article-title":"The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience","volume":"53","author":"Youssef","year":"2012","journal-title":"J Nucl Med"},{"key":"2023102011135254400_jead137-B66","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2967\/jnumed.117.196287","article-title":"Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"58","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Med"},{"key":"2023102011135254400_jead137-B67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MCP.0000000000000611","article-title":"Treatment of cardiac sarcoidosis","volume":"25","author":"Kouranos","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2023102011135254400_jead137-B68","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023102011135254400_jead137-B69","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 Esc\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2023102011135254400_jead137-B70","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European association of cardiovascular imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jead137\/51721325\/jead137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/24\/10\/1343\/51770005\/jead137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/24\/10\/1343\/51770005\/jead137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:17:18Z","timestamp":1697800638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/24\/10\/1343\/7218494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jead137","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,3]]}}}